Profile data is unavailable for this security.
About the company
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
- Revenue in USD (TTM)797.03k
- Net income in USD-34.91m
- Incorporated1998
- Employees110.00
- LocationVolitionRX Ltd1489 West Warm Springs Road, Suite 110HENDERSON 89014United StatesUSA
- Phone+1 (646) 650-1351
- Fax+65 6333-7235
- Websitehttps://volition.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reneo Pharmaceuticals Inc | 0.00 | -70.71m | 55.48m | 8.00 | -- | 0.6829 | -- | -- | -2.17 | -2.17 | 0.00 | 2.43 | 0.00 | -- | -- | 0.00 | -77.06 | -- | -83.08 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
| Immix Biopharma Inc | 0.00 | -18.21m | 55.73m | 14.00 | -- | 2.00 | -- | -- | -0.9263 | -0.9263 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -77.50 | -- | -90.46 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.44 | -- | -- | -- |
| Mural Oncology PLC | 0.00 | -191.90m | 56.86m | 117.00 | -- | 0.242 | -- | -- | -11.49 | -11.49 | 0.00 | 13.88 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
| Protara Therapeutics Inc | 0.00 | -42.47m | 57.86m | 26.00 | -- | 0.5501 | -- | -- | -3.74 | -3.74 | 0.00 | 5.11 | 0.00 | -- | -- | 0.00 | -48.67 | -37.02 | -52.23 | -38.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 38.71 | -- | -17.67 | -- |
| Cidara Therapeutics Inc | 46.38m | -36.47m | 57.89m | 69.00 | -- | -- | -- | 1.25 | -8.07 | -8.07 | 10.26 | -3.90 | 0.6899 | -- | 2.80 | 672,144.90 | -54.24 | -65.23 | -218.59 | -154.37 | 76.93 | -- | -78.63 | -100.61 | 0.6047 | -- | -- | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
| VolitionRX Ltd | 797.03k | -34.91m | 58.45m | 110.00 | -- | -- | -- | 73.33 | -0.4603 | -0.4603 | 0.0104 | -0.1901 | 0.0425 | -- | 6.32 | 7,245.73 | -188.25 | -111.92 | -- | -196.20 | -- | -- | -4,425.95 | -10,793.31 | -- | -173.85 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
| AN2 Therapeutics Inc | 0.00 | -66.03m | 59.36m | 41.00 | -- | 0.5365 | -- | -- | -2.59 | -2.59 | 0.00 | 3.71 | 0.00 | -- | -- | 0.00 | -62.19 | -- | -68.38 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
| LAVA Therapeutics NV | 12.54m | -28.59m | 59.41m | 37.00 | -- | 1.17 | -- | 4.74 | -1.07 | -1.07 | 0.4668 | 1.93 | 0.107 | -- | 9.09 | 338,837.80 | -24.40 | -- | -28.91 | -- | 79.64 | -- | -228.02 | -- | -- | -- | 0.108 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
| Turnstone Biologics Corp | 0.00 | -74.92m | 60.37m | 82.00 | -- | 0.7545 | -- | -- | -3.53 | -3.53 | 0.00 | 3.46 | 0.00 | -- | -- | 0.00 | -80.25 | -- | -94.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -73.66 | -- | -78.05 | -- | -- | -- |
| Enzo Biochem Inc | 32.80m | -23.31m | 60.96m | 179.00 | -- | 0.8489 | -- | 1.86 | -0.4699 | 0.6708 | 0.6586 | 1.40 | 0.3738 | 1.61 | 4.10 | 183,257.00 | -26.56 | -12.21 | -39.50 | -15.79 | 42.17 | 37.09 | -71.07 | -18.76 | 2.89 | -- | 0.0476 | -- | -4.85 | -21.01 | -23.02 | -- | 7.89 | -- |
| Calcimedica Inc | 0.00 | -14.94m | 61.05m | 14.00 | -- | 3.54 | -- | -- | -2.64 | -2.64 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -48.34 | -63.99 | -66.59 | -72.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.51 | -- | -44.35 | -- |
| Curis Inc | 9.81m | -47.73m | 61.06m | 48.00 | -- | 6.45 | -- | 6.22 | -8.68 | -8.68 | 1.77 | 1.61 | 0.1253 | -- | 4.39 | 204,416.70 | -60.97 | -37.25 | -69.58 | -41.12 | 97.60 | 96.05 | -486.45 | -409.44 | -- | -- | 0.00 | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -7.45m | 61.16m | 12.00 | -- | 3.58 | -- | -- | -0.5863 | -0.5863 | 0.00 | 1.31 | 0.00 | -- | -- | 0.00 | -82.73 | -- | -113.11 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.15 | -- | -- | -- |
| Champions Oncology Inc | 49.22m | -9.73m | 61.58m | 230.00 | -- | -- | -- | 1.25 | -0.7183 | -0.7183 | 3.64 | -0.1514 | 1.56 | -- | 6.17 | 214,017.40 | -30.91 | -5.40 | -96.45 | -11.88 | 40.09 | 47.96 | -19.76 | -3.09 | -- | -- | -- | -- | 9.69 | 21.63 | -1,073.54 | -- | 18.50 | -- |
Data as of May 31 2024. Currency figures normalised to VolitionRX Ltd's reporting currency: US Dollar USD
9.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Lagoda Investment Management LPas of 31 Mar 2024 | 5.07m | 6.18% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 622.45k | 0.76% |
| Geode Capital Management LLCas of 31 Mar 2024 | 617.37k | 0.75% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 565.41k | 0.69% |
| Bridgeway Capital Management LLCas of 31 Mar 2024 | 174.18k | 0.21% |
| Silverberg Bernstein Capital Management LLCas of 31 Mar 2024 | 144.62k | 0.18% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 134.00k | 0.16% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 123.92k | 0.15% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 89.39k | 0.11% |
| Spectrum Asset Management, Inc. (California)as of 31 Mar 2024 | 55.60k | 0.07% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
